BOSTON & DURHAM, N.C.--(BUSINESS WIRE)--Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through to Commercialization, today announced Gavin Nichols has joined the company as Executive Vice President, Informatics and Information Technology. In his role Mr. Nichols will lead the Parexel Informatics (PI) business as well as the company’s Information Technology (IT) function, driving the development of innovative technology-enabled services and solutions as well as a best-in-class digital infrastructure. Mr. Nichols joins Parexel from BioClinica, where he served as Chief Information Officer and Executive Vice President of Technology. He will serve on Parexel’s Executive Leadership team and be based in the company’s Nottingham, UK office.
“Now more than ever it’s critical that science and technology come together to advance drug development,” said Chief Executive Officer Jamie Macdonald. “Gavin’s extensive experience leading global technology teams in the pharmaceutical and healthcare space provide the perfect blend of expertise to drive the development of innovative technologies and solutions for our customers in a constantly evolving and growing clinical trial landscape. We look forward to his leadership as we work to grow our PI business and deliver a best-in-class technology infrastructure, practices and systems for the global Parexel organization.”
Prior to joining Parexel, Mr. Nichols held various global leadership roles in technology, leading strategic and innovative transformations in the pharmaceutical and healthcare sectors. Most notably, his experience includes 11 years with Quintiles (now IQVIA), where he served as Vice President, Data/Analytics/Innovation IT and was instrumental in the creation of its Infosario technology suite. Mr. Nichols also served as Vice President, Life Science, at Perspectum Diagnostics, as well as President, Technology and Software, at Cetara. His wide range of experience includes leading the delivery of data analytics, recruitment, wearables, electronic health records, genetics, consumer apps and trial management solutions. Mr. Nichols holds a Master of Business Administration from Bournemouth University and a Bachelor of Science from Open University.
Parexel is focused on supporting the development of innovative new therapies to improve patient health. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit our website and follow us on LinkedIn, Twitter and Instagram.
Parexel is a registered trademark of Parexel International Corporation. All other trademarks are the property of their respective owners.